Brokerages Expect Nabriva Therapeutics plc (NASDAQ:NBRV) Will Announce Earnings of -$0.21 Per Share

Analysts expect Nabriva Therapeutics plc (NASDAQ:NBRV) to report ($0.21) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Nabriva Therapeutics’ earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.24). Nabriva Therapeutics posted earnings per share of ($1.11) during the same quarter last year, which indicates a positive year-over-year growth rate of 81.1%. The firm is expected to announce its next quarterly earnings results on Thursday, March 10th.

On average, analysts expect that Nabriva Therapeutics will report full year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($1.08). For the next financial year, analysts expect that the business will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.67) to ($0.42). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow Nabriva Therapeutics.

Separately, Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Saturday, November 13th.

NBRV remained flat at $$0.85 during trading on Friday. The company had a trading volume of 997,933 shares, compared to its average volume of 2,087,916. The stock has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.20. The company has a market capitalization of $461.69 million, a price-to-earnings ratio of -0.40 and a beta of 1.62. Nabriva Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.58. The company has a current ratio of 4.48, a quick ratio of 4.40 and a debt-to-equity ratio of 0.08.

In other Nabriva Therapeutics news, CEO Theodore R. Schroeder purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 14th. The stock was bought at an average cost of $1.13 per share, with a total value of $56,500.00. Following the completion of the transaction, the chief executive officer now owns 226,875 shares of the company’s stock, valued at approximately $256,368.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.93% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Clear Creek Financial Management LLC bought a new position in shares of Nabriva Therapeutics in the second quarter worth $27,000. Advisor Group Holdings Inc. raised its position in Nabriva Therapeutics by 5,200.0% during the third quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 26,000 shares in the last quarter. Millennium Management LLC purchased a new stake in Nabriva Therapeutics during the second quarter valued at about $42,000. Two Sigma Securities LLC purchased a new stake in Nabriva Therapeutics during the third quarter valued at about $48,000. Finally, Geode Capital Management LLC increased its holdings in shares of Nabriva Therapeutics by 102.9% in the third quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after buying an additional 21,672 shares during the period. 0.71% of the stock is owned by institutional investors and hedge funds.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Featured Article: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.